# A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)

> **NCT05419401** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 7 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** Capivasertib film-coated tablet, 200 mg
- **DRUG:** [14C]AZD5363 (Capivasertib)

## Key facts

- **NCT ID:** NCT05419401
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-11
- **Primary completion:** 2022-07-12
- **Final completion:** 2022-07-12
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2022-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05419401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05419401, "A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05419401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*